Analysts Unconvinced By Sanofi Best-In-Class Claims For Sarclisa
Much Ground To Make Up On J&J's Darzalex
Executive Summary
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.
You may also be interested in...
Sanofi Challenges J&J’s Darzalex With Blackstone Pact For SC Sarclisa
The French major has entered a risk-sharing collaboration with Blackstone focused on a new formulation of multiple myeloma drug Sarclisa, which could help it take on market leader Darzalex.
$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform
The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.
GSK To Address Multiple Myeloma With First-In-Class Blenrep In EU
The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.